FIELD: pharmaceuticals.
SUBSTANCE: invention refers to pharmaceutical industry and provides a pharmaceutical composition containing croscarmellose sodium, hyaluronic acid and a non-steroid anti-inflammatory drug in acid form for local treatment of exuding skin lesions, where croscarmellose makes up at least 90 wt% of said composition, where non-steroid anti-inflammatory drug in acid form is diclofenac in concentration from 0.4 to 3.0 wt% with respect to total weight of said composition and wherein hyaluronic acid has weight-average molecular weight (MW) of 130 to 230 kDa, and concentration of 0.1 to 4 wt% with respect to total weight of said composition.
EFFECT: invention provides considerable exudate absorption and high painkilling activity.
11 cl, 5 ex, 4 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITION WITH ANTIBACTERIAL AND WOUND-HEALING ACTIVITY | 2011 |
|
RU2611046C2 |
| NIMESULIDE-CONTAINING SUSTAINED-RELEASE COMPOSITIONS | 2000 |
|
RU2238087C2 |
| COMPLEXES BASED ON CHONDROITIN FOR CUTANEOUS ABSORPTION | 2013 |
|
RU2642612C2 |
| COMPOSITIONS CONTAINING POLYSACCHARIDE MATRIX FOR CONTROLLED RELEASE OF ACTIVE INGREDIENTS | 2017 |
|
RU2748261C2 |
| DERIVATIVE OF HYALURONIC ACID AND MEDICAL AGENT THAT CONTAINS IT | 2005 |
|
RU2390529C2 |
| IMMEDIATE RELEASE PHARMACEUTICAL COMPOSITIONS CONTAINING KETOPROFEN LYSINE SALT | 2019 |
|
RU2804350C2 |
| DISULPHIRAM IMPLANT FOR TREATING ALCOHOL OR OPIATE ADDICTIVE PATIENTS | 2012 |
|
RU2495679C1 |
| OROMUCOUS NANOFIBER CARRIERS FOR THERAPEUTIC TREATMENT | 2017 |
|
RU2751508C2 |
| IMPLANTED DRUG PREPARATION OF NALTREXONE FOR TREATING ALCOHOL- OR OPIOID-DEPENDENT PATIENTS | 2012 |
|
RU2476209C1 |
| IMPLANTABLE MEDICATION DISULFIRAM-BASED FOR TREATMENT OF ALCOHOL OR OPIATE-DEPENDENT PATIENT | 2012 |
|
RU2475272C1 |
